Search - tctmd.com

Displaying 161 - 180 of 342

Sort: Relevancy | Date

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

News Daily News

Rural-Urban Gap Widens for Cardiometabolic Health Disparities

Michael O'Riordan

June 22, 2020

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Todd Neale

May 06, 2020

News Daily News

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Yael L. Maxwell

April 28, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

Meat Consumption Linked to Small Rises in CVD, All-Cause Mortality Risks

Michael O'Riordan

February 05, 2020

News Daily News

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Yael L. Maxwell

January 16, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Todd Neale

November 18, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

Advertisement

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Rural-Urban Gap Widens for Cardiometabolic Health Disparities

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Meat Consumption Linked to Small Rises in CVD, All-Cause Mortality Risks

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content